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Abstract

Rationale:

β1ARs (β1-adrenoceptors) exist at intracellular membranes and OCT3 (organic cation transporter 3)
mediates norepinephrine entry into cardiomyocytes. However, the functional role of intracellular β1AR
in cardiac contractility remains to be elucidated.

Objective:

Test localization and function of intracellular β1AR on cardiac contractility.

Methods and Results:

Membrane fractionation, super-resolution imaging, proximity ligation, coimmunoprecipitation, and
single-molecule pull-down demonstrated a pool of β1ARs in mouse hearts that were associated with
sarco/endoplasmic reticulum Ca2+-ATPase at the sarcoplasmic reticulum (SR). Local PKA (protein kinase
A) activation was measured using a PKA biosensor targeted at either the plasma membrane (PM) or SR.
Compared with wild-type, myocytes lacking OCT3 (OCT3-KO [OCT3 knockout]) responded identically to
the membrane-permeant βAR agonist isoproterenol in PKA activation at both PM and SR. The same
was true at the PM for membrane-impermeant norepinephrine, but the SR response to norepinephrine
was suppressed in OCT3-KO myocytes. This differential effect was recapitulated in phosphorylation of
the SR-pump regulator phospholamban. Similarly, OCT3-KO selectively suppressed calcium transients
and contraction responses to norepinephrine but not isoproterenol. Furthermore, sotalol, a
membrane-impermeant βAR-blocker, suppressed isoproterenol-induced PKA activation at the PM but
permitted PKA activation at the SR, phospholamban phosphorylation, and contractility. Moreover,
pretreatment with sotalol in OCT3-KO myocytes prevented norepinephrine-induced PKA activation at
both PM and the SR and contractility.

Conclusions:

Functional β1ARs exists at the SR and is critical for PKA-mediated phosphorylation of phospholamban
and cardiac contractility upon catecholamine stimulation. Activation of these intracellular β1ARs
requires catecholamine transport via OCT3.

Introduction

Plasma membrane receptors are major mechanisms by which cells respond to extracellular stimuli,
allowing cells to adapt to their surrounding environments and to modulate tissue/organ function in
reaction to changes of neurohormones. Nonsteroid hormones signal mainly through receptors at the
plasma membrane (PM) to regulate cellular function. This includes sympathetic regulation of cardiac
function via ARs (adrenergic receptors) on the PM of cardiomyocytes. Recently, a complementary
thread of studies has found that neurotransmitters, peptide hormones, and growth factors also act on
intracellular membrane receptors.1–4 Accumulating data indicate that intracellular GPCRs (G-protein
coupled receptors) located at different organelles, for example, mitochondria,5 endoplasmic reticulum
membranes,6 and Golgi,7 can be activated insides the cells and induce location-specific effects. The
development of these observations helps expanding the current understanding of hormonal regulation
of cardiac function.
β1ARs (β1-adrenoceptors), a prototype GPCR, acts as a linchpin of sympathetic regulation in the heart
and has been demonstrated to be localized and activated intracellularly in cardiomyocytes.8 However,
the role of intracellular β1ARs in the regulation of cardiac excitation-contraction is still unknown.
During the fight-or-flight response, activation of the sympathetic nerve and adrenal glands releases
catecholamines (epinephrine, and norepinephrine) to activate βARs on myocytes and thus enhance
heart rate, cardiac contraction and relaxation.9,10 These effects involve βARs stimulation-dependent
cAMP (cyclic adenosine monophosphate) and subsequent activation of PKA (protein kinase A) to
enhance substrate phosphorylation. The PKA phosphorylation of different substrates occurs in
different spatiotemporal nanodomains including LTCC (L-type Ca2+ channel) at the PM, PLB

(phospholamban) and RyR2 (ryanodine receptor type 2) on the sarcoplasmic reticulum (SR), and TnI
(troponin I) and MYBP-C (myosin binding protein C) on the myofilaments.11,12
Both norepinephrine and epinephrine are vital neurohormones in physiological stress responses.
However, epinephrine and norepinephrine have extremely hydrophilic octanol/water partition
coefficients (LogP =−1.37 and −1.24, respectively, https://pubchem.ncbi.nlm.nih.gov). After release
from nerve termini, a small portion of catecholamine can enter myocytes, primarily mediated by
corticosterone-sensitive OCT3 (organic cation transporter 3, also named EMT [extraneuronal
monoamine transporter]).2,13 OCT3-mediated norepinephrine uptake is necessary for activation of
intracellular ARs in cardiomyocytes, including both nuclear α1ARs and Golgi-localized
β1ARs.2,8 Intriguingly, decreased norepinephrine uptake into myocardium and cardiac norepinephrine
contents in patients with heart failure (HF) are associated with significantly blunted inotropy
response.14 In dilated cardiomyopathy patients, OCT2 expression is reduced and predicts the
impairment of cardiac function.15 However, the functional role of norepinephrine uptake facilitated by
OCT3 in adrenergic stimulation of cardiac contractile is unclear.
Activation of β1ARs induces spatial, temporal segregated cAMP-PKA signals in heart.12,16 The
application of Förster resonance energy transfer (FRET)–based biosensors have been instrumental in
the investigation and dissection of compartmentalized cAMP/PKA signaling on the nanodomain
scale.12,17,18 By using genetically encoded biosensors, previous studies from our group and others found
that compartmentalized cAMP/PKA signal generated in response to βAR stimulation differs at the PM
and SR local domains in both amplitude and kinetics.12,17 The mechanism underlying this heterogeneity
is still unclear. We hypothesize that a population of β1ARs is located near or at the SR and plays an
important role in modulating calcium (Ca2+) cycling and cardiac contractility. In this study, we tested
the expression, activation, and functional effects of SR-localized β1AR in cardiac contractility. Our
results provide novel insights into the localization and regulation of intracellular β1AR, therefore,
offering potential and precise target for β1AR-associated therapeutic strategies.

Methods
Data Availability

The data, analytic methods, and study materials are made available to other researchers for purposes
of reproducing the results or replicating the procedure. Please see the Major Resources Table and
Expanded Materials & Methods in the Data Supplement.
All experiments including animal feeding, treatment, and tissue collection were approved by the
Institutional Animal Care and Use Committees (protocol: 20234 and 20957) of the University of
California at Davis and follow National Institutes of Health guidelines. Male and female 2- to 4-monthold C57/BL6 and OCT3-KO, newborn β1AR-KO, β2AR-KO, and β1β2AR-KO mice were described
previously.17,19 Male Sprague Dawley outbred rats and New Zealand white rabbits were used in this
study.

Results
Existence and Distribution of a Distinct Pool of β1AR at the SR in Cardiomyocytes

To examine the existence of different subcellular pools of β1ARs in adult mouse hearts, we fractionated
heart tissues to separate the PM from intracellular membrane compartments. SERCA2 (sarcoplasmic
endoplasmic reticulum Ca2+-ATPase 2) and RyR2, which are SR resident proteins, were used as markers
for the intracellular membrane fraction (non-PM), and InsR (insulin receptor) and lack of SERCA2/RyR2
were used to identify PM fraction. β1ARs were clearly detected in both PM and intracellular membrane
fractions (non-PM) in wild-type (WT) mouse hearts but not in β1AR-KO mouse hearts (Figure 1A and
Figure IA in the Data Supplement), indicating that endogenous β1AR exists in at least 2 different pools
in mouse hearts. In addition, quantitative radioligand-binding assay measured the functional β1ARs
that bind to [I125] radio-labeled cyanopindolol in both PM and intracellular membrane fractions (Figure
1B), supporting the existence of an intracellular pool of functional β1ARs in hearts. We also applied a
fluorescence dye BODIPY-tagged βAR antagonist propranolol (BODIPY-tagged propranolol [FL-Prop]) to
stain endogenous β1ARs in mouse adult ventricle myocytes (AVMs). Confocal images of FL-Prop
fluorescent staining in WT mouse AVMs showed a distribution of βARs on both surface membrane and
intracellular space (Figure IB in the Data Supplement), which was abrogated by addition of 1 μmol/L
and 10 μmol/L propranolol (Figure IB in the Data Supplement). Moreover, compared with WT and
β2AR-KO cardiomyocytes, the fluorescent dots and intensity of FL-Prop were greatly reduced in the
β1AR-KO and β1β2AR-KO cardiomyocytes (Figure IC and ID in the Data Supplement), indicating that FLProp mainly stains endogenous β1AR.

Figure 1. Intracellular β1AR (β1-adrenoceptors) associates with SERCA2 (sarcoplasmic endoplasmic reticulum
Ca2+-ATPase 2) but not RyR2 (ryanodine receptor type 2) in hearts and isolated mouse adult ventricular
cardiomyocytes (AVMs).A, Wild-type (WT) and β1AR-knockout (KO) mouse heart lysates were fractionated to
assess cellular distribution of β1AR. Representative blots and the percentages of β1AR in the plasma membrane
(PM) and intracellular membrane fractions (non-PM) over the total β1AR in WT and β1AR-KO mouse hearts. Data

are shown in mean±SEM. N=9 mice. P values were obtained by Student t test. B, β1AR densities in the PM and
non-PM fractions of WT mouse hearts were determined by quantitative radioligand-binding assay. Data are
shown in mean±SEM. N=6 mice. P values were obtained by Student t test. C and D, Representative confocal
images showing distribution of β1AR, SERCA2, and RyR2 in isolated mouse AVMs. β1AR was overexpressed in
AVMs by infection with recombinant adenovirus. Scale bar=5 μm. E, The overlap between staining from confocal
images was evaluated by Pearson correlation coefficient using ImageJ. Data are shown in mean±SEM; AVM (in
the parenthesis) and mouse numbers are indicated in the figure. P value was obtained by t test. F, Schematic of
in situ proximity ligation assay (PLA), exemplary fluorescence images (the whole-cell images are in Figure II in
the Data Supplement) and quantification of PLA signals after labeling with antibodies against β1AR and IgG,
β1AR and SERCA2, and β1AR and RyR2 in AVMs, respectively. Positive PLA signal (red), DAPI (4′,6-diamidino-2phenylindole) (blue). Scale bar=5 μm. Data are shown in mean±SEM; AVM (in the parenthesis) and mouse
numbers are indicated. P values were obtained by 1-way ANOVA followed by Tukey multiple comparison test. G,
Representative images and quantitative assessment of PLB (phospholamban), SERCA2, and RyR2
coimmunoprecipitated with β1AR in WT mouse hearts. Arbitrary unit (A.U) is defined as the ratio of intensity of
proteins over inputs. Data are shown in mean±SEM (N=5); P values were obtained by Student t test; H,
Schematic of supersensitive single-molecule pull-down (SiMPull) assay and representative images of SiMPull
assay after endogenous β1AR, SERCA2 complex were pulled down with anti-β1AR or control IgG antibodies. The
images were quantified using MATLAB. Scale bar=5 μm. Data are shown in mean±SEM. N=5 mice. P values were
obtained by t test. InsR indicates insulin receptor; and IP, immunoprecipitation.

SR-localized Ca2+ cycling proteins, such as SERCA2 and RyR2, are crucial for the modulation of cardiac
contractility in response to βAR activation.11 We hypothesize that a population of intracellular β1ARs
are present at the SR. We examined a potential colocalization of overexpressed β1AR with SERCA2 or
RyR2. β1AR displayed specific colocalization with SERCA2, but not RyR2, in mouse AVMs (Figure 1C
through 1E and Figure IIA in the Data Supplement). As controls, overexpressed β2AR did not display
overlap with either SERCA2 or RyR2 (Figure IIIA and IIIB in the Data Supplement). Next, we applied
proximity ligation assay to further explore the proximal relationship between β1AR and SERCA2. We
detected robust proximity ligation assay signals in mouse AVMs costained for β1AR and SERCA2,
suggesting that these β1ARs and SERCA2 are at ≤40 nm apart. Conversely, proximity ligation assay
signals were not detected after costaining with antibodies against β1AR and IgG or against β1AR and
RyR2 and only a small amount of proximity ligation assay signals was detected after costaining for β1AR
and JP2 (junctophilin 2; Figure 1F and Figure IIB through IID in the Data Supplement). Moreover,
endogenous β1AR was pulled down with β1AR antibody (Figure 1G). We found that both SERCA2 and its
regulatory protein, PLB, were coimmunoprecipitated with the endogenous β1ARs. In contrast, RyR2
was not observed in the immunoprecipitation. Furthermore, we applied a supersensitive singlemolecule pull-down assay20 to visualize individual β1AR-SERCA2 complex in heart lysate. Figure
1H shows that β1AR antibody was able to pull-down a significant amount of SERCA2 molecules
compared with control IgG antibody. Together, these data demonstrate that a population of β1ARs is
localized at the SR and forms a complex with SERCA2 in AVMs.

OCT3 Is Required to Activate the Pool of β1ARs by Catecholamine at the SR

β-adrenoceptor stimulation results in activation of PKA, a key mediator for phosphorylating multiple
Ca2+ handling proteins (eg, PLB).21 To directly assess PKA activity induced by the SR-localized β1AR, we
employed a genetically encoded Förster resonance energy transfer–based AKAR (A kinase activity
reporter) that is anchored at the intracellular SERCA2 complex on the SR (SR-AKAR3).17,18 In

comparison, the PKA activity induced by the PM-localized β1AR was assessed by an AKAR3 anchored on
the PM (PM-AKAR3).
Previous studies showed that OCT3-mediated transportations of epinephrine or norepinephrine into
cells are essential for activating intracellular adrenergic receptors in cardiomyocytes.2,8 Here, we used
mice with genetic deletion of OCT3 to examine the impacts of OCT3 on subcellular PKA activity induced
by PM- or SR-localized β1AR (PM-β1AR or SR-β1AR). Unlike endogenous catecholamines, isoproterenol
(LogP=1.4) and dobutamine (LogP=3.6), 2 membrane-permeant β agonists, activate internal βAR via
passive diffusion into myocytes (Figure 2A and 2B).7 Therefore, deleting OCT3 should selectively block
the access of norepinephrine and epinephrine but not isoproterenol and dobutamine to SR-localized
β1AR (Figure 2A and 2B). Norepinephrine, epinephrine, isoproterenol, and dobutamine all induced
robust PKA activity at both the PM and SR in WT myocytes (Figure IVA through IVD in the Data
Supplement). The kinetics of ligand-induced PKA activity at the PM was comparable but were faster
than those at the SR (Figure IVA through IVE in the Data Supplement). Among the SR-PKA activity, the
dobutamine-induced increases were faster than those by isoproterenol, epinephrine, and
norepinephrine, consistent with its faster membrane permeability (Figure IVA through IVE in the Data
Supplement). As predicted, the isoproterenol-induced PKA activity at both the PM and SR was not
affected by deletion of OCT3 (Figure 2C through 2D). However, deletion of OCT3 selectively attenuated
norepinephrine-induced PKA activity at the SR without affecting PKA activity at the PM (Figure
2E and 2F). Moreover, inhibition of β1AR with CGP20712a completely abolished PKA activity induced by
norepinephrine and isoproterenol at both PM and the SR in AVMs, whereas inhibition of β2AR with
ICI118551 did not affect these PKA activities (Figure IVF through IVI in the Data Supplement). These
observations were not due to change in β1AR expression in OCT3-KO hearts (Figure V in the Data
Supplement). Additionally, we have examined PKA activity at the myofilaments with an AKAR3
anchored on the troponin complex (myofilament-AKAR318), which is adjacent to the SR. Our data show
deletion of OCT3 selectively attenuated norepinephrine but not isoproterenol-induced PKA activity on
the myofilaments (Figure VA in the Data Supplement). To explore specific PKA substrate affected by SRlocalized β1AR activation, we then examined PKA phosphorylation of PLM (phospholemman, Ser63) and
LTCC (Ser1928) at the PM, PLB (Ser16) and RyR2 (Ser2808) at the SR, TnI (Ser23/24), and MYBP-C (Ser282,
Ser273, Ser302) at myofilament. Deletion of OCT3 selectively attenuated norepinephrine-induced PKA
phosphorylation of PLB and TnI without affecting PKA phosphorylation of PLM, LTCC, RyR2, and MYBPC (Figure 2G and 2H and Figure VB through VH in the Data Supplement). In comparison, isoproterenolinduced PKA phosphorylation of both PLM and PLB was not affected by OCT3 deficiency (Figure
2G and 2H). These data suggest that deletion of OCT3 blocks catecholamine-dependent activation of
the β1ARs at the SR and the myofilament and downstream PKA-dependent PLB and TnI
phosphorylation.

Figure 2. Differential local regulation of norepinephrine (NE)-induced β1AR (β1-adrenoceptors)/PKA (protein
kinase A) activities in wild-type (WT) and OCT3-KO (organic cation transporter 3 knockout) adult ventricular
cardiomyocytes (AVMs).A and B, Schematics of local activation of β1AR-induced PKA activity at subcellular
locations and detection using Förster resonance energy transfer (FRET) based biosensors (plasma membrane,
plasma membrane (PM)-AKAR (A kinase activity reporter) 3 and sarcoplasmic reticulum [SR]-AKAR3) in WT and
OCT3-KO AVMs. Isoproterenol (ISO), norepinephrine (NE). FRET assay was analyzed with F/F0 of emission ratio
of YFP (527nm) to CFP (476nm), YFP/CFP ratio. C and D, Concentration-response curves of changes in YFP/CFP
ratio after ISO stimulation in WT and OCT3-KO AVMs expressing PM-AKAR3 or SR-AKAR3. Data were from 6 WT
and 6 OCT3-KO mice. E and F, Concentration-response curves of changes in YFP/CFP ratio after NE stimulation in
WT and OCT3-KO AVMs expressing PM-AKAR3 or SR-AKAR3. Data were from 8 WT and 7 OCT3-KO mice. Data
are shown in mean±SEM. P values were obtained by 2-way ANOVA with Tukey multiple comparison test when
comparing WT to OCT3-KO. G and H, Detection of pPLB (phosphorylation of phospholamban) at serine 16 and
pPLM at serine 63 in mouse AVMs after stimulation with 100 nmol/L ISO or 100 nmol/L NE. Data are shown in
mean±SEM (N=5). AU (arbitrary unit) is defined as the ratio of intensity of phosphorylated proteins over
intensity of total proteins. P values were obtained by 2-way ANOVA with Tukey multiple comparison test. A.U
indicates arbitrary unit; and SERCA2, sarcoplasmic endoplasmic reticulum Ca2+-ATPase 2.

Functional Consequences of the Internal Pool of β1ARs on Adult Ventricular Myocyte

We then assessed whether the deletion of OCT3 affects catecholamine-induced Ca2+ handling and
sarcomere shortening in isolated AVMs. Compared with basal conditions, stimulation with different
βAR agonists (isoproterenol, dobutamine, norepinephrine, and epinephrine) led to increased
sarcomere shortening and Ca2+ transient amplitude and decreased Ca2+ decay tau in both WT and
OCT3-KO AVMs (Figure 3A through 3H and Figure VIA through VIK in the Data Supplement).
Dobutamine induced a faster inotropic response than isoproterenol and norepinephrine in WT AVMs.
The increases in excitation-contraction coupling were blocked by β1AR antagonist CGP20712a but not
affected by β2AR inhibition with ICI118551 (Figure VII in the Data Supplement). Deletion of OCT3 did
not affect isoproterenol- or dobutamine-induced inotropic responses (Figure 3A through 3D and Figure
VID through VIK in the Data Supplement). Conversely, the norepinephrine- and epinephrine-promoted

responses in contraction, Ca2+ transients, and [Ca2+]i decay tau were significantly attenuated in OCT3KO versus WT AVMs (Figure 3E through 3H and Figure VIJ through VIK in the Data Supplement).
Deletion of OCT3 also shifted the norepinephrine dose-response curve of sarcomere shortening to the
right without affecting isoproterenol-induced dose-response curve (Figure 3I and 3J).

Figure 3. Deletion of OCT3 (organic cation transporter 3) attenuates stimulation of myocyte contractility with
norepinephrine (NE) and epinephrine (EPI).A and B, Representative traces show sarcomere shortening (SS)
before (close line) and after (dash line) stimulation with isoproterenol (ISO; 100 nmol/L) in the wild-type (WT)
and OCT3-knockout (KO) mouse adult ventricular cardiomyocytes (AVMs). The peak SS were quantified. C and D,
Representative traces show fractional shortening before (close line) and after (dash line) the application of
dobutamine (Dob, 1μmol/L) in WT and OCT3-KO AVMs. The peak SS were quantified. E and F, Representative
traces show SS before (close line) and after (dash line) the application of NE (100 nmol/L) in WT and OCT3-KO
AVMs. The peak SS were quantified. G and H, Representative traces show SS before (close line) and after (dash
line) the application of EPI (epinephrine,100 nmol/L) in WT and OCT3-KO AVMs. The peak SS were quantified.
For A–H, data are shown in mean±SEM. AVM (in the parenthesis) and animal numbers are indicated. P values
were obtained by 2-way ANOVA analysis followed by Tukey multiple comparison test. I and J, Dose-response
curves of SS in AVMs after stimulation with ISO (7 WT and 7 OCT3-KO mice) or NE (6 WT and 8 OCT3-KO
mice). P values were obtained by 2-way ANOVA with Tukey multiple comparison test when comparing OCT3-KO
to WT. SERCA2 indicates sarcoplasmic endoplasmic reticulum Ca2+-ATPase 2.

To independently test the role of OCT3 in the SR-located β1AR/PKA signaling, we applied an OCT3/EMT
inhibitor corticosterone to prevent norepinephrine transport into myocytes (Figure 4A and 4B). While
corticosterone had minimal effect on norepinephrine-induced PKA activity at the PM domain, it

significantly attenuated norepinephrine-induced PKA activity at the SR domain (Figure 4C and 4D).
Corticosterone did not change isoproterenol-induced PKA activity at either the PM or SR domain in rat
AVM (Figure 4C and 4D). In agreement, corticosterone significantly reduced norepinephrine- but not
isoproterenol-induced PKA phosphorylation of PLB at Ser16 (Figure 4E and 4F). Corticosterone also
significantly attenuated norepinephrine-induced increases in contractility, Ca2+ transient amplitude,
and rate of Ca2+ transient decay (Figure 4G through 4I). However, these corticosterone effects were
absent in the responses to isoproterenol stimulation (Figure 4J through 4L). Together, these data
suggest that OCT3-dependent transport is required for stimulation of SR-localized β1AR/PKA/PLB signal
cascade for optimal increases in Ca2+ handling and contractility.

Figure 4. Inhibition of organic catecholamine transporters reduces norepinephrine (NE)-promoted
sarcoplasmic reticulum (SR)-localized β1AR (β1-adrenoceptors) signal and myocardial contractility.A and B,
Schematics show detection of β1AR-induced PKA (protein kinase A) activity at different subcellular locations with
and without OCT3 (organic cation transporter 3) inhibitor corticosterone (CORTI). C and D, Rat adult ventricular
cardiomyocytes (AVMs) expressing plasma membrane (PM)-AKAR (A kinase activity reporter) 3 or SR-AKAR3
Förster resonance energy transfer (FRET) biosensor were pretreated with CORTI (corticosterone,1 μmol/L)
before stimulation with NE (100 nmol/L) or isoproterenol (ISO; 100 nmol/L). FRET was analyzed as F/F0 of
YFP/CFP ratio. Data show the maximal increases in YFP/CFP ratios in mean±SEM. AVM (in the parenthesis) and
rat numbers are indicated. P values were obtained by 1-way ANOVA with Tukey multiple comparison
test. E and F, Representative immunoblot detection and quantification of phosphorylated serine 16 (pPLB) and
total PLB (phospholamban) in rat AVMs. Cells were treated with 5-minute incubation with ISO (100 nmol/L) or
NE (100 nmol/L) in the absence and presence of CORTI pretreatment. AU (arbitrary units) is defined as the ratio
of intensity of phosphorylated proteins over intensity of total proteins. Data are shown in mean±SEM
(N=3). P values were obtained by 1-way ANOVA with Tukey multiple comparison test. G–L, Rat AVMs were
loaded with Ca2+ indicator, 5 μmol/L Fluo-4 AM, and pretreated with CORTI (1 μmol/L) before stimulation with
NE (100 nmol/L) or ISO (100 nmol/L). Sarcomere shortening (SS) and calcium transient amplitude and tau were
recorded with 1 Hz pacing. Data are shown in mean±SEM. AVM (in the parenthesis) and animal numbers are
indicated in figures. P values were obtained by 1-way ANOVA with Tukey multiple comparison test.

Activation of the Internal β1ARs at the SR Was not Blocked by Membrane-Impermeant
β-Blockers

Sotalol, a membrane-impermeant β-blocker (LogP=0.24), has limited access to intracellular β1AR.22 To
further dissect the physiological function of the SR-β1AR, we applied sotalol to selectively block the
PM-β1AR but permit access and activation of SR-β1AR by agonists. In contrast, propranolol, a
membrane-permeant β-blocker (LogP=3.48), is expected to block βARs both on the PM and at
intracellular membranes (Figure VIIIA in the Data Supplement). We tested the accessibilities of sotalol
and propranolol to the β1ARs by examining their abilities to compete with fluorescent FL-Prop from
binding to β1ARs. Confocal images of FL-Prop fluorescent staining in WT mouse AVMs showed a
distribution of βAR on both surface and intracellular membranes (Figure VIIIB in the Data Supplement).
Sotalol pretreatment did not block the intracellular staining (Figure VIIIB in the Data Supplement),
whereas addition of propranolol effectively competed against FL-Prop from binding to β1AR in AVMs
(Figure VIIIB in the Data Supplement). Addition of isoproterenol and norepinephrine also effectively
competed against FL-Prop from binding to β1AR in AVMs. Thus, intracellular β1AR can be blocked by
membrane-permeant β-blockers but are less accessible to membrane-impermeant β-blockers.
Sotalol was then applied to isolate PKA activity induced by local compartmentalized β1AR at the SR
(Figure 5A through 5C). In WT, β1AR-KO, and β2AR-KO mouse neonatal myocytes and WT mouse, rat,
and rabbit AVMs, sotalol readily inhibited isoproterenol-induced and β1AR mediated PKA activity at the
PM but not those at the SR (Figure 5D through 5G, Figures IXA through IXD and Figure X in the Data
Supplement). In rat AVMs, the IC50 of sotalol for inhibition of isoproterenol-induced PKA activity at the
SR was about 10-fold higher than that of PKA activity at the PM (Figure 5G, PM-AKAR3 IC50=2.22±0.06
μmol/L; SR-AKAR3 IC50=21.5±0.06 μmol/L). In contrast, the membrane-permeant β-blocker propranolol
inhibited isoproterenol-induced PKA activity at both the PM and SR in a concentration-dependent
manner (Figure 5F, PM-AKAR3 IC50=74.0±0.05 nmol/L, SR-AKAR3 IC50=99.2±0.06 nmol/L). Another
poorly permeant β-blocker, atenolol (LogP=0.6), acted similarly to sotalol by selectively inhibiting
isoproterenol-induced PKA activity only at the PM in rat AVMs (Figure IXE and IXF in the Data
Supplement). In comparison, membrane-permeant carvedilol (LogP=4.19) inhibited isoproterenolinduced PKA activity at both the PM and the SR (Figure IXE and IXF in the Data Supplement). Together,
these data support that local activation of SR-β1AR-PKA signaling was minimally suppressed by
membrane-impermeant β-blockers, a conserved mechanism throughout different cardiac myocytes
from different species. This also indicates that the β1AR at the SR is not activated at the PM and then
translocated to the SR.

Figure 5. Activation of β1AR (β1 -adrenoceptors) in the sarcoplasmic reticulum (SR) is essential for
maximal stimulated contractility in adult ventricular cardiomyocytes (AVMs).A–C, Schematics show
detection of β1AR-induced PKA (protein kinase A) activity at different subcellular locations (plasma
membrane [PM] and SR) with Förster resonance energy transfer (FRET) based biosensors in the
presence of membrane-impermeant β-blocker sotalol (SOTA) or the membrane-permeant β-blocker
propranolol (PROP). D and E, Rat AVMs expressing PM-AKAR (A kinase activity reporter) 3 or SR-AKAR3
were stimulated with 100 nmol/L isoproterenol (ISO) with 5-min pretreatment of 25 μmol/L SOTA
(blue) or 1 μmol/L PROP (red) or without pretrement (CON). Representative time courses show FRET
response of PM-AKAR3 or SR-AKAR3 in AVMs. FRET was analyzed as F/F0 of YFP/CFP ratio. Data are
shown in mean±SEM. AVM (in the parenthesis) and rat numbers are indicated. P values were obtained
by 1-way ANOVA analysis with Tukey multiple comparison test. F and G, Dose-dependent inhibition
curves of PROP or SOTA on ISO-induced increases in FRET responses in AVMs expressing PM-AKAR3 or
SR-AKAR3. Data show YFP/CFP ratios normalized against the maximal increases induced by ISO in the
absence of β-blocker (N=5 rats). P values were obtained by 2-way ANOVA analysis followed by Tukey
multiple comparison test when compared with OCT3-KO (organic cation transporter 3 knockout) (PMAKAR3: PROP, IC50=7.399×10-8 mol/L, SR-AKAR3: PROP, IC50=9.92×10-8 mol/L; PM-AKAR3: SOTA,
IC50=2.216×10-6 mol/L; SR-AKAR3, STOA, IC50=2.149×10-5 mol/L). H–J, Rat AVMs were incubated with
Ca2+ indicator (5 μmol/L Fluo-4 AM) before 1 Hz pacing. After pretreatment with SOTA (25 μmol/L) or
PROP (1 μmol/L), sarcomere shortening (SS) and calcium transient were recorded before and after
stimulation with 100 nmol/L ISO. The peak SS, amplitude of Ca2+ transient, and rate of Ca2+ decay (Tau)
are shown as mean±SEM. Animal numbers and cell numbers are indicated in figures. P values were
obtained by 1-way ANOVA analysis with Tukey multiple comparison test. SERCA2 indicates
sarcoplasmic endoplasmic reticulum Ca2+-ATPase 2.

Activation of the β1AR at the SR Promotes Optimal Cardiac Contractility and
Ca2+ Handling in AVMs

Consistent with the PKA activity detected at the SR, sotalol blocked isoproterenol-induced PKA
phosphorylation of LTCC at Ser1928 but did not affect isoproterenol-induced PKA phosphorylation of PLB
at Ser16 in mouse, rat, or rabbit AVMs (Figure XI in the Data Supplement). However, propranolol
abolished isoproterenol-induced phosphorylation of PLB and LTCC (Figure XI in the Data Supplement).
These data support that activation of the SR-β1AR signaling promotes SR-localized PKA phosphorylation
of PLB in AVMs. Accordingly, isoproterenol-induced increases in sarcomere shortening, Ca2+ transient
amplitude, and decreases in tau were partially reduced by sotalol but completely abolished by
propranolol in rat AVMs (Figure 5H through 5J). These data suggest that phosphorylation of PLB by PKA
is mediated by localized β1AR signaling at the SR and promotes myocyte contractility.

Similarly, sotalol selectively inhibited norepinephrine-induced PKA activity at the PM yet permitted
increases in PKA activity in the SR local domain (Figure 6A through 6D and Figure XIIA through XIIF in
the Data Supplement). We then assessed whether OCT3 controls the norepinephrine-induced local PKA
activity at the SR in the presence of sotalol. Deletion of OCT3 abolished PKA activity at the SR domain
induced by norepinephrine in the presence of sotalol (Figure 6A and 6B and Figure XIIA through XIIF in
the Data Supplement). In contrast, isoproterenol-induced PKA activity at the SR was not affected by
OCT3-KO and sotalol pretreatment (Figure 6C and 6D). In the presence of sotalol, deleting OCT3
completely blocked norepinephrine-induced increases in sarcomere shortening, Ca2+transient, and
decreases in Ca2+ decay tau (Figure 6E through 6G) but did not affect the responses induced by
isoproterenol (Figure 6H through 6J). These data show that in the presence of membrane-impermeant
β-blocker sotalol, norepinephrine can selectively stimulate SR-β1AR signaling to promote local PKA
activity and enhance myocyte contractility. These activities can be blocked by deletion of OCT3 that is
responsible for uptake of norepinephrine into AVMs.

Figure 6. Activation of β1AR (β1-adrenoceptors) at the sarcoplasmic reticulum (SR) promotes myocyte calcium
cycling and contractility.A and B, Wild-type (WT) and OCT3-KO (organic cation transporter 3 knockout) adult

ventricular cardiomyocytes (AVMs) were used to express plasma membrane (PM)-AKAR (A kinase activity
reporter) 3 or SR-AKAR3 biosensors. Förster resonance energy transfer (FRET) was analyzed as F/F0 of YFP/CFP
ratio. Representative curves and maximal changes show subcellular PKA (protein kinase A) FRET responses to
norepinephrine (NE; 100 nmol/L) stimulation in AVMs pretreated with sotalol (SOTA, 25 μmol/L). Animal
numbers and cell numbers (in the parenthesis) are indicated. P values were obtained by 2-way ANOVA analysis
followed by Tukey multiple comparison test when compared to OCT3-KO. C and D, WT and OCT3-KO mouse
AVMs were used to express PM-AKAR3 or SR-AKAR3 biosensors. Representative curves and maximal changes
show subcellular PKA FRET responses to isoproterenol (ISO; 100 nmol/L) stimulation in AVMs pretreated with
sotalol (SOTA, 25 μmol/L). Animal numbers and cell numbers (in the parenthesis) are indicated. P values were
obtained by 2-way ANOVA analysis followed by Tukey multiple comparison test when compared to OCT3-KO. E–
G, AVMs from WT and OCT3 hearts were stimulated with NE (100 nmol/L) in the presence of SOTA (25 μmol/L)
pretreatment. Data show maximal changes in sarcomere shortening (SS), Ca2+ transient amplitude, and rate of
Ca2+ decay (Tau) as mean±SEM. Animal numbers and cell numbers (in the parenthesis) are indicated in
figures. P values were obtained by 2-way ANOVA analysis with Tukey multiple comparison test. H–J, AVMs from
WT and OCT3 hearts were stimulated with ISO (100 nmol/L) in the presence of SOTA (25 μmol/L) pretreatment.
Data show maximal changes in SS, Ca2+ transient amplitude, and Tau as mean±SEM. Animal numbers and cell
numbers (in the parenthesis) are indicated. P values were obtained by 2-way ANOVA analysis with Tukey
multiple comparison test.

OCT3 Deficiency Impairs Catecholamine Transport in Heart and Attenuates EpinephrineInduced Inotropy and Heart Rate In Vivo
Finally, we sought to understand the impacts of intracellular β1AR activation on adrenergic regulation
of cardiac function in vivo. We observed no differences in heart weight/body weight ratios of OCT3-KO
and WT mice (Figure 7A), indicating a grossly normal cardiac structure in OCT3-KO hearts. However,
deletion of OCT3 reduced endogenous norepinephrine concentration in hearts compared with WT
controls, whereas OCT3-KO and WT mice had comparable norepinephrine concentrations in the
plasma (Figure 7B and 7C). Consequently, OCT3-KO mice show lower cAMP concentrations in hearts
relative to WT controls (Figure 7D). These data indicate disrupted catecholamine transport and
potential intracellular adrenergic receptor activation by OCT3 deletion. Compared with WT, OCT3-KO
mice showed no difference in cardiac function, including ejection fraction and heart rate at baseline
conditions (Figure 7E through 7I). These observations obtained by echocardiography are probably
relevant to adaptive gene expressions in myocardium due to OCT3 deletion. The expression of PLB and
PLB/SERCA2 ratio were decreased whereas expression of RyR2 was increased in OCT3-KO hearts
(Figure XIIIA and XIIIB in the Data Supplement). Furthermore, we detected cardiac β-adrenergic
response with 10 microg/kg epinephrine or isoproterenol injection in vivo. Compared with WT, OCT3KO mice showed no difference in cardiac function after 10 microg/kg isoproterenol administration
(Figure 7G through 7I). However, OCT3-KO displayed significantly blunted ejection fraction and heart
rate responses to epinephrine injection relative to WT (Figure 7G through 7I). These data show that
OCT3 is essential for enhancing myocardial contractility induced by epinephrine in vivo.

Figure 7. Deletion of OCT3 (organic cation transporter 3) reduces catecholamine uptake, cAMP (cyclic
adenosine monophosphate) signal, and inotropic response in response to adrenergic stimulation of mouse
hearts.A, Heart weight/body weight ratio (HW/BW %) in wild-type (WT) and OCT3-knockout (KO) mice. Data are
shown as mean±SEM (N=8). P values were obtained by Student t test. B and C, Quantitative determination of
endogenous norepinephrine (NE) in cardiac tissues and the plasma. Data are shown as mean±SEM
(N=8). P values were obtained by Student t test. D, Quantitative determination of cAMP levels in cardiac tissues.
Data are shown as mean±SEM (N=4). P values were obtained by Student t test. E, Representative
echocardiographic images of WT (N=7) and OCT3-KO (N=6) mice at baseline and after intraperitoneal injection of
10 μg/kg isoproterenol (ISO) or epinephrine (EPI). F–I, Cardiac ejection fraction (EF) of individual mice before
and after intraperitoneal injection of ISO or EPI in WT (N=7) and OCT3-KO (N=6). Quantification of EF and heart
rate (HR) in WT and OCT3-KO mice before and after injection with ISO or EPI. Data are shown as
mean±SEM. P values were obtained by 2-way ANOVA analysis with Tukey multiple comparison test.

Discussion

Adrenergic signaling is one of the most important mechanisms for regulating cardiac function and is
typically blunted/disturbed in cardiac diseases including HF.23 In this study, we provide evidence to
support the presence of a pool of β1ARs at the SR that is essential for enhancing contractility in
cardiomyocytes. We also show that monoamine transporter OCT3/EMT–mediated catecholamine
uptake is essential for activation of the SR-β1AR and for promoting phosphorylation of PLB by PKA and
cardiac contractility. Furthermore, our data suggest that different clinically used β-blockers differ
significantly in their ability to suppress internal β1AR-PKA signaling due to different membrane
permeability. Although membrane-permeant β blockers, such as propranolol and carvedilol, are able to
block activation of intracellular β1ARs, membrane-impermeant β-blockers, such as sotalol and atenolol,
cannot readily access intracellular β1AR. Therefore, this study opens a novel avenue to optimize
therapeutic strategies for targeting cardiac β1 adrenergic signaling in different clinical settings.

Intracellular Adrenergic Receptor Signaling at the SR

Accumulating evidence suggests the presence of GPCRs and G proteins inside mammalian
cells.24 Increasing number of intracellular GPCRs have been identified in animal hearts, including
angiotensin3 and adrenergic receptors.2,8 In cardiomyocytes, previous studies have characterized both
β1 and α1ARs but not β2AR on the nuclear envelope.1,2 β1ARs were also found to reside in the Golgi
apparatus and initiate an internal G protein-stimulated cAMP signal from the Golgi apparatus, and this
internal signal is independent of receptors at the PM.7,8 However, whether ARs are localized at other
subcellular locations and their functional implications in cardiac contractility remain to be elucidated.
Here, we used a combination of sophisticated molecular probes, genetically modified mice, and
pharmacological inhibitors to uncover important details of the intracellular β1AR-cAMP-PKA pathway at
the SR. We provide solid evidence of the presence of intracellular β1ARs at the SR in cardiomyocytes,
which is associated with SERCA2 and PLB, consistent with a recent report that exogenously expressed
β1ARs bind to SERCA2 in fibroblasts.25 Meanwhile, our data do not support the presence of a cardiac
β2AR-SERCA2 complex at the SR membrane. This identification of SR-localized β1ARs provides a novel
possibility to explain precisely compartmentalized β1AR signaling in cardiomyocytes. Upon βAR
activation, the locally anchored PKA is activated and promotes phosphorylation of targets within a
nanodomain, including LTCC at the PM, PLB on the SR, and troponin I and myosin binding protein C on
the myofilaments.12,18,26 The present work shows that activation of the intracellular β1ARs at the SR is
necessary for promoting local PKA activity to phosphorylate PLB and TnI in cardiomyocytes and
probably plays a more critical role in rate-limiting cardiac outputs during the physiological fight-orflight responses. The intracellular β1AR and PKA activity was essential to optimize enhancement of
Ca2+ transients and cardiac contractility. Yet, much remains to be learnt about the composition,
regulation, and function of this emerging β1AR signaling machinery at the SR in hearts.

Requirement of Catecholamine Uptake for Intracellular β1ARs Activation

Based on lipophilicity, different βARs ligands access intracellular β1AR either by passive diffusion or
transporter-mediated uptake. For instance, the current and prior studies show that hydrophilic
catecholamine norepinephrine and epinephrine require OCT3/EMT for cellular uptake,2 whereas
hydrophobic ligands (eg, isoproterenol) can passively cross the PM.7,8 During sympathetic stimulation,
catecholamine is released from nerve termini to stimulate adrenergic receptors on cardiomyocytes.
Extracellular catecholamines are quickly reduced mainly by reuptake at nerve termini.27 However,
cardiomyocytes can also take up a portion of catecholamines via OCT3/EMT.28 A key question is raised
by these observations: what is the function of the catecholamine uptake into cardiomyocytes?
Traditionally, it is considered as a mechanism to clear excess catecholamines to prevent
overstimulation of cardiac adrenergic signaling.14 However, recent research revealed that intracellular
norepinephrine activates Golgi-localized β1ARs to promote PI4P hydrolysis.8 In this work, for the first
time, we show that inhibition of norepinephrine uptake by OCT3/EMT reduces intracellular PKA activity
at the SR as well as contractility in cardiomyocytes. Accordingly, OCT3/EMT dependent-catecholamine
uptake is essential for optimal βAR-induced enhancement of contractility in cardiac muscles. Deletion
of OCT3 attenuated epinephrine-induced increases in cardiac ejection fraction. Meanwhile, deletion of
OCT3 also blunted epinephrine-induced increases in cardiac heart rate, supporting a notion that SR
Ca2+ content contributes to sinoatrial nodal pacemaker cells for physiological heart rate
increases.29 Further studies may be merited to address impacts of intracellular β1ARs activation on SR

Ca2+ content and Ca2+ handling in myocytes. It also remains to be examined whether other transporters
such as OCT2 may affect activation of intracellular β1ARs in hearts. These observations highlight the
transporter-dependent uptake of catecholamines as a potential drug target for clinical applications in a
variety of cardiovascular conditions.
Similarly, clinically used β-blockers differ significantly in their membrane permeability. Carvedilol is a
commonly used β-blocker in HF therapy, and it can permeate the PM and inhibit β1AR at both the PM
and intracellular membrane compartments. Thus, it may potentially inhibit detrimental effects of
chronic activation of the intracellular β1AR such as nuclear PKA activity for maladaptive gene
expression. In comparison, membrane-impermeant β-blockers such as sotalol and atenolol, which
should mainly block β1AR only at the PM,7,8 are not widely used for HF therapy. Nonetheless, these βblockers are effective as anti-arrhythmic drugs,30 probably in part due to their ability to inhibit β1AR on
the PM. Our study thus provides a conceptual platform to evaluate and assess individual β-blockers for
more efficacious therapy in different clinical applications.

Integrity of β1ARs at the Cell Surface and Subcellular Membrane

Recent and previous studies indicate that the activation of intracellular βAR/PKA signal generates
localization-specific and substrate-specific effects.7,8 Membrane localization of βARs and their
associated complexes precisely fine-tune βAR activation, which is essential to maintain the cellular
function and appropriate responses to extracellular stimuli, such as catecholamines.16,26 More
importantly, we found that the integral regulation of β1AR at both cell surface and the SR is required to
achieve maximal enhancement of cardiac contraction via optimally coordinating PKA-dependent
phosphorylation of substrates in multiple loci. Impaired integrity of β1AR/cAMP/PKA signaling and
blunted cardiac contractile response to β-adrenergic stimulation have been implicated in pathological
stress conditions.26 It has been reported that in HF βAR activation-induced PKA activity is significantly
inhibited or abolished at the SR and at the myofilaments, but well-preserved at the PM,12,18 suggesting
the dysregulation of intracellular βAR/PKA signal is involved in the pathogenesis of HF. Besides, a large
body of studies revealed that in human HF, norepinephrine reuptake was impaired.31 Although cardiac
norepinephrine release by sympathetic nerves was increased in patients with HF, cardiac
norepinephrine uptake and cardiac norepinephrine contents were significantly reduced. Accordingly,
OCT transporters expression is reduced in dilated cardiomyopathy patients.15 Those observations are
consistent with our findings in OCT3-KO mice that disrupted catecholamine uptake leads to decreased
norepinephrine concentrations and cAMP in the myocardium. Meanwhile, OCT3-KO mice show
attenuated inotropic response to catecholamines. Taken together, these findings suggest a decreased
activation of intracellular β1AR at the SR due to dysregulated OCT3 may contribute to the decreased
PKA activity and phosphorylation of PLB associated with cardiac dysfunction. The integrity β1ARs at
intracellular membranes and their role in development of HF remain to be further explored.
In summary, this study uncovers a novel signaling paradigm in which an SR-localized intracellular β1AR
is functionally crucial in adrenergic stimulation of cardiac contractility. Moreover, the data not only
help to broaden our current understanding of the general role of β1AR signaling in cardiac regulation
but also open up a novel platform to evaluate and optimize β-blockers in clinical applications based on
their biased properties in selective inhibition of cardiac β1AR at distinct subcellular locations.
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Novelty and Significance
What Is Known?
•

β1ARs (β1-adrenoceptors) are the major subtype driving cardiac contractility in response to
catecholamine stimulation.

•

β1ARs exist in intracellular membranes.

•

OCT3 (organic cation transporter 3) mediates norepinephrine entry into cardiomyocytes.

What New Information Does This Article Contribute?
•

A pool of β1ARs are associated with the SERCA2 (sarcoplasmic endoplasmic reticulum Ca2+ATPase 2) complex at the sarcoplasmic reticulum (SR).

•

Activation of the SR-localized β1AR is essential to promote phosphorylation of phospholamban.

•

Organic Cation transporter 3 is required for catecholamines (norepinephrine and epinephrine)
to enter cells and stimulate the β1AR at the SR.

•

Activation of intracellular SR β1AR is essential to promote cardiac contractility.

Functional β1ARs exists at the SR and is critical for PKA (protein kinase A)-mediated phosphorylation of
phospholamban and cardiac contractility upon catecholamine stimulation. Activation of these

intracellular β1ARs requires catecholamine transport via OCT3. For decades, catecholamines have been
shown to signal via βARs on the plasma membrane to regulate heart contractile functions. Little is
known about the presence and function of intracellular βARs in cardiomyocytes. We show the
presence of intracellular β1AR associated with SERCA2 on the SR. Activation of this SR-localized β1AR is
essential for promoting PKA-dependent phosphorylation of PLB (phospholamban) and optimizing the
cardiac contraction response. Intracellular β1AR activation is regulated by catecholamine uptake via the
OCT3 transporter or membrane-permeant β-blockers in cardiomyocytes. These findings provide new
mechanistic insight into the composition, localization, and regulation of β1AR signaling. Targeting
intracellular β1AR and its regulators could have potential therapeutic utility in diseases related to
cardiac contractile function.

